RE:RE:Germany BoomingStarkicker wrote: The German market is nice but it's a false hope on moving the SP up. LABS sold $1.4M in Germany in Q1. Even if that doubles, which it won't in Q2, we're still talking miniscule sales. Australia is about the same.
The company’s sales of medical cannabis into the German market were $1.4 million, a 36% increase from the previous quarter. The majority of these sales (70%) were non-flower cannabis products, including oil, CBD isolate, and dronabinol, a synthetic form of THC.
MediPharm’s
Agreed 100%. Which is something I have a hard time reconciling. If the market is booming and we have a Stada in our corner, how is it that sales don't materially increase?
The post was less a point about how much (or little really) that LABS sells in Germany, and more about the fact that the market is growing by leaps and bounds and LABS should be taking part. If not, why not??